This app will help dementia patients in restoring memories

Hypertension may impair the brain far earlier than previously understood -- even before a measurable rise in blood pressure occurs -- according to a new preclinical study from Weill Cornell Medicine. The changes help explain why hypertension is a major risk factor for developing cognitive disorders, such as vascular cognitive impairment and Alzheimer's disease.

A novel, error-corrected technique for identifying cancer from blood samples is significantly more sensitive and accurate than previous methods and could be helpful for monitoring patients' disease status following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.

Working towards more effective tuberculosis (TB) vaccinations, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that may be activated to stop the bacteria after they elicit an immune response.

Brain inflammation, while an important aspect of the immune response, plays a negative effect in Alzheimer's disease. Unlike the acute, short-lived inflammation that fights infection, the inflammation associated with Alzheimer's is chronic and persistent. Scientists have been trying to figure out why this happens

A study reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta -- a hallmark of Alzheimer's disease. The findings suggest that vascular dysfunction could be an early driver in neurodegenerative disorders rather than being caused by neuronal damage.

When most people think of dementia, particularly Alzheimer's disease, they often think of memory loss first.

Long-term data from a landmark international trial show that about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors live cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Centre investigators and colleagues.

It is now simpler to differentiate between primary tauopathy and Alzheimer's thanks to a novel biomarker.

Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7 per cent lower risk of developing Alzheimer's disease and related dementia later in life, according to a new study

Alzheimer's disease, the most common type of dementia, currently affects twice as many women as men, with minority populations predicted to witness the most significant increase in cases in the coming years, according to the Centers for Disease Control and Prevention